News | May 21, 2026
Takeda Pharma ordered to pay $2.5 billion in Amitiza case
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The target reach is of more than 30 million young people and caregivers across 21 countries
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
Company handles 20,000+ AI-driven calls and chats daily as it scales agentic AI systems across healthcare workflows
The standout story remains Wegovy, particularly its new oral formulation
The private funding rose 38% amid growing international collaborations and CDMO demand
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
